Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | OMC | THC |
|---|---|---|
| Price | $75.11 | $255.13 |
| Change today | ▲ 2.00% | ▼ 0.17% |
| Market cap | $20.60B | $20.54B |
| Return, 3 months | -0.3% | +33.4% |
| Return, year to date | -4.1% | +28.4% |
| Return, 1 year | +1.0% | +26.7% |
| P/E (TTM) | 203.0 | 9.9 |
| P/B | 2.1 | 4.4 |
| P/E percentile vs own 5y | 96th | 46th |
| Dividend yield | 4.13% | – |
| Revenue growth (YoY, latest qtr) | +63.4% | +14.6% |
| Net profit growth (YoY) | +118.0% | +100.2% |
| Gross margin | 11.2% | 82.8% |
| Operating margin | 5.0% | 19.5% |
| Net margin | 1.7% | 9.9% |
| Return on equity | 5.5% | 53.3% |
| Analyst target vs. price | +33.4% | +11.1% |
| Analyst buy share | 60% | 89% |
| RSI (14) | 33 | 46 |
| 30-day volatility | 27.8% | 29.0% |
| Max drawdown, 1 year | -17.8% | -34.1% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
